Molecular Therapy · 2014 · 52 citations · 37 references
MedicineGeneticsNeuroscienceGene DeliveryMolecular NeurobiologyMolecular NeuroscienceGene Delivery VectorsMotor Neuron DiseasesNeurodegenerative DiseasesNeurodegenerative DisordersNeuromuscular JunctionSpinal Muscular AtrophyAdeno-associated Viral VectorsGene-targeted TherapyNeuromuscular Gene TherapyNeuromuscular Junction PathologyPediatric Spinal Muscular AtrophyPten InactivationSmn1 Gene DeletionTherapeutic Modulation
Spinal muscular atrophy (SMA) is the second most common genetic cause of death in childhood. However, no effective treatment is available to halt disease progression. SMA is caused by mutations in the survival motor neuron 1 (SMN1) gene. We previously reported that PTEN depletion leads to an increase in survival of SMN-deficient motor neurons. Here, we aimed to establish the impact of PTEN modulation in an SMA mouse model in vivo. Initial experiments using intramuscular delivery of adeno-associated vector serotype 6 (AAV6) expressing shRNA against PTEN in an established mouse model of severe SMA (SMNΔ7) demonstrated the ability to ameliorate the severity of neuromuscular junction pathology. Subsequently, we developed self-complementary AAV9 expressing siPTEN (scAAV9-siPTEN) to allow evaluation of the effect of systemic suppression of PTEN on the disease course of SMA in vivo. Treatment with a single injection of scAAV9-siPTEN at postnatal day 1 resulted in a modest threefold extension of the lifespan of SMNΔ7 mice, increasing mean survival to 30 days, compared to 10 days in untreated mice. Our data revealed that systemic PTEN depletion is an important disease modifier in SMNΔ7 mice, and therapies aimed at lowering PTEN expression may therefore offer a potential therapeutic strategy for SMA. Spinal muscular atrophy (SMA) is the second most common genetic cause of death in childhood. However, no effective treatment is available to halt disease progression. SMA is caused by mutations in the survival motor neuron 1 (SMN1) gene. We previously reported that PTEN depletion leads to an increase in survival of SMN-deficient motor neurons. Here, we aimed to establish the impact of PTEN modulation in an SMA mouse model in vivo. Initial experiments using intramuscular delivery of adeno-associated vector serotype 6 (AAV6) expressing shRNA against PTEN in an established mouse model of severe SMA (SMNΔ7) demonstrated the ability to ameliorate the severity of neuromuscular junction pathology. Subsequently, we developed self-complementary AAV9 expressing siPTEN (scAAV9-siPTEN) to allow evaluation of the effect of systemic suppression of PTEN on the disease course of SMA in vivo. Treatment with a single injection of scAAV9-siPTEN at postnatal day 1 resulted in a modest threefold extension of the lifespan of SMNΔ7 mice, increasing mean survival to 30 days, compared to 10 days in untreated mice. Our data revealed that systemic PTEN depletion is an important disease modifier in SMNΔ7 mice, and therapies aimed at lowering PTEN expression may therefore offer a potential therapeutic strategy for SMA.
37
Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN
Vuk Stambolic, Akira Suzuki, José Luís de la Pompa et al. · Cell · 1998 · 2.6K citations · Full text
Promoting Axon Regeneration in the Adult CNS by Modulation of the PTEN/mTOR Pathway
Kevin K. Park, Kai Liu, Yang Hu et al. · Science · 2008 · 1.7K citations · Full text
Medicine, Neurobiology, Neuroscience +16
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Kevin D. Foust, Emily Nurre, Chrystal L. Montgomery et al. · Nature Biotechnology · 2008 · 1.4K citations · Full text
PTEN deletion enhances the regenerative ability of adult corticospinal neurons
Kai Liu, Yi Lu, Jae K. Lee et al. · Nature Neuroscience · 2010 · 990 citations · Full text